Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

NCT02875002 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Relapsed and Refractory Aggressive B- and T-cell Lymphomas
Lymphoma

Interventions

DRUG: volasertib
DRUG: belinostat

Sponsor

Yale University

Collaborators

[object Object]
[object Object]